NEKTAR THERAPEUTICS STOCK OPTION AGREEMENTStock Option Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations
Pursuant to the Stock Option Grant Notice (“Option Notice”) and this Stock Option Agreement, Nektar Therapeutics (the “Company”) has granted you an option under its 2000 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in the Option Notice at the exercise price indicated in the Option Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
DATE] [NAME] [ADDRESS] Dear [NAME]:Severance Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations
In connection with your continued leadership as [TITLE] of Nektar Therapeutics (“Nektar” or the “Company”), I present you with this letter agreement setting forth certain severance benefits to be afforded to you under certain circumstances (the “Letter Agreement”). Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Company’s Amended and Restated Change of Control Severance Benefit Plan, as it may be further amended from time to time (the “COC Plan”).
NEKTAR THERAPEUTICS RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations • California
Pursuant to your Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Agreement (“Agreement”) (collectively, the “Award”), Nektar Therapeutics (the “Company”) has awarded you, pursuant to its 2000 Equity Incentive Plan (the “Plan”), the number of Restricted Stock Units as indicated in the Grant Notice. Defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan.
EMPLOYMENT TRANSITION AND SEPARATION RELEASE AGREEMENTEmployment Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations
Nektar Therapeutics (“Nektar” or “Company”) hereby offers you a severance package in connection with the future termination of your employment with the Company. This Employee Transition and Separation Release Agreement (“Agreement”) describes the severance benefits and other terms of your separation transition.
EMPLOYMENT TRANSITION AND SEPARATION RELEASE AGREEMENTSeverance Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations
Nektar Therapeutics (“Nektar” or “Company”) hereby offers you a severance package in connection with your future termination of employment from the Company. This Severance Package Release Agreement (“Agreement”) describes the severance package and other terms of your separation transition.
NEKTAR THERAPEUTICS, AEROGEN, INC., AND BAYER HEALTHCARE LLC CO-DEVELOPMENT, LICENSE AND CO-PROMOTION AGREEMENT AUGUST 1, 2007Co-Development, License and Co-Promotion Agreement • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations • New York
* $10 million of this payment shall be repaid to Bayer if Bayer terminates this Agreement within thirty (30) days following delivery by Nektar to Bayer of the final report for the [***].
AMENDED AND RESTATED BUILT-TO-SUIT LEASE By and Between Inhale 201 Industrial Road, L.P. a California Limited Partnership, as LANDLORD And Nektar Therapeutics (fka Inhale Therapeutic Systems, Inc.), a Delaware Corporation, as TENANT 201 Industrial...Built-to-Suit Lease • November 9th, 2007 • Nektar Therapeutics • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED BUILD-TO-SUIT LEASE (“Lease”) is made and entered into as of August 17, 2004 by and between INHALE 201 INDUSTRIAL ROAD, L.P., a California limited partnership (“Landlord”), and NEKTAR THERAPEUTICS (FKA INHALE THERAPEUTIC SYSTEMS, INC.), a Delaware corporation (“Tenant”).
